COMPANY

Arietis Pharma

HQ: Boston, MA source · arietis.org ↗ · New England

Keywords: small molecule

Location: Boston, MA · source · Oct 15, 2026

Profile checked Oct 10, 2026

31NIH grants

NIH awards 31

Annual award amounts. Total $27.4M.

Aug 14, 2025 NIH award 5R44AI179382-03 FY2025: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI LAFLEUR, MICHAEL; recipient as written: ARIETIS, Boston, MA. Development of a Dual-Targeting ClpP Activating Antibiot source ↗
Aug 8, 2024 NIH award 5R44AI179382-02 FY2024: $999,619 awarded for that fiscal year; activity R44 (SBIR); PI LAFLEUR, MICHAEL; recipient as written: ARIETIS, Boston, MA. Development of a Dual-Targeting ClpP Activating Antibiotic source ↗
Aug 29, 2023 NIH award 1R44AI179382-01 FY2023: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI LAFLEUR, MICHAEL; recipient as written: ARIETIS, Boston, MA. Development of a Dual-Targeting ClpP Activating Antibiot source ↗
Mar 9, 2023 NIH award 5R44AI157081-03 FY2023: $995,100 awarded for that fiscal year; activity R44 (SBIR); PI LAFLEUR, MICHAEL; recipient as written: ARIETIS, Boston, MA. A New Approach to Treat Prosthetic Joint Infections with a source ↗
Nov 8, 2022 NIH award 5R01AI141193-05 FY2023: $1,186,918 awarded for that fiscal year; activity R01 (OTHER_NIH); PI LAFLEUR, MICHAEL; recipient as written: ARIETIS, Boston, MA. Development of ureadepsipetides for drug-resistant source ↗
Feb 17, 2022 NIH award 5R44AI157081-02 FY2022: $996,046 awarded for that fiscal year; activity R44 (SBIR); PI LAFLEUR, MICHAEL; recipient as written: ARIETIS, Boston, MA. A New Approach to Treat Prosthetic Joint Infections with a source ↗
Nov 12, 2021 NIH award 5R01AI141193-04 FY2022: $1,200,871 awarded for that fiscal year; activity R01 (OTHER_NIH); PI LAFLEUR, MICHAEL; recipient as written: ARIETIS, Boston, MA. Development of ureadepsipetides for drug-resistant source ↗
Mar 5, 2021 NIH award 1R44AI157081-01 FY2021: $995,100 awarded for that fiscal year; activity R44 (SBIR); PI LAFLEUR, MICHAEL; recipient as written: ARIETIS, Boston, MA. A New Approach to Treat Prosthetic Joint Infections with a source ↗
Nov 25, 2020 NIH award 5R01AI141193-03 FY2021: $1,209,617 awarded for that fiscal year; activity R01 (OTHER_NIH); PI LAFLEUR, MICHAEL; recipient as written: ARIETIS, Boston, MA. Development of ureadepsipetides for drug-resistant source ↗
Nov 27, 2019 NIH award 5R01AI141193-02 FY2020: $1,235,145 awarded for that fiscal year; activity R01 (OTHER_NIH); PI LAFLEUR, MICHAEL; recipient as written: ARIETIS, Boston, MA. Development of ureadepsipetides for drug-resistant source ↗
Dec 17, 2018 NIH award 1R01AI141193-01 FY2019: $1,529,042 awarded for that fiscal year; activity R01 (OTHER_NIH); PI LAFLEUR, MICHAEL; recipient as written: ARIETIS, Boston, MA. Development of ureadepsipetides for drug-resistant source ↗
Feb 23, 2018 NIH award 5R44AI122426-03 FY2018: $1,248,159 awarded for that fiscal year; activity R44 (SBIR); PI LAFLEUR, MICHAEL; recipient as written: ARIETIS, Boston, MA. Bactericidal antibiotic for Vancomycin Resistant Enteroc source ↗
Apr 20, 2017 NIH award 5R44AI112187-04 FY2017: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI COLEMAN, KENNETH; recipient as written: ARIETIS, Boston, MA. Antibiotics for Recalcitrant Infection source ↗
Feb 22, 2017 NIH award 5R44AI122426-02 FY2017: $1,251,577 awarded for that fiscal year; activity R44 (SBIR); PI LAFLEUR, MICHAEL; recipient as written: ARIETIS, Boston, MA. Bactericidal antibiotic for Vancomycin Resistant Enteroc source ↗
Apr 22, 2016 NIH award 5R44AI112187-03 FY2016: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI COLEMAN, KENNETH; recipient as written: ARIETIS, Boston, MA. Antibiotics for Recalcitrant Infection source ↗
Mar 14, 2016 NIH award 1R44AI122426-01A1 FY2016: $1,218,307 awarded for that fiscal year; activity R44 (SBIR); PI LAFLEUR, MICHAEL; recipient as written: ARIETIS, Boston, MA. Bactericidal antibiotic for Vancomycin Resistant Enter source ↗
Jun 24, 2015 NIH award 5R44AI102452-04 FY2015: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI COLEMAN, KENNETH; recipient as written: ARIETIS, Boston, MA. Narrow-spectrum Agents Acting against Helicobacter pylor source ↗
Apr 9, 2015 NIH award 4R44AI112187-02 FY2015: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI COLEMAN, KENNETH; recipient as written: ARIETIS, Boston, MA. Antibiotics for Recalcitrant Infection source ↗
Jun 26, 2014 NIH award 5R44AI102452-03 FY2014: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI COLEMAN, KENNETH; recipient as written: ARIETIS, Boston, MA. Narrow-spectrum Agents Acting against Helicobacter pylor source ↗
May 14, 2014 NIH award 1R44AI112187-01A1 FY2014: $300,000 awarded for that fiscal year; activity R44 (SBIR); PI COLEMAN, KENNETH; recipient as written: ARIETIS, Boston, MA. Antibiotics for Recalcitrant Infection source ↗
Jul 1, 2013 NIH award 4R44AI102452-02 FY2013: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI COLEMAN, KENNETH; recipient as written: ARIETIS, Boston, MA. Narrow-spectrum Agents Acting against Helicobacter pylor source ↗
Jun 4, 2013 NIH award 5R43AI098327-02 FY2013: $290,070 awarded for that fiscal year; activity R43 (SBIR); PI COLEMAN, KENNETH; recipient as written: ARIETIS, Boston, MA. Compounds to treat Helicobacter pylori infection source ↗
Jun 28, 2012 NIH award 5R44AI074258-05 FY2012: $979,417 awarded for that fiscal year; activity R44 (SBIR); PI DAHL, THOMAS A; recipient as written: ARIETIS, Boston, MA. Therapy Against Recalcitrant C. albicans Infection source ↗
Jun 22, 2012 NIH award 1R44AI102452-01 FY2012: $297,456 awarded for that fiscal year; activity R44 (SBIR); PI COLEMAN, KENNETH; recipient as written: ARIETIS, Boston, MA. Narrow-spectrum Agents Acting against Helicobacter pylori source ↗
Jun 13, 2012 NIH award 1R43AI098327-01 FY2012: $295,897 awarded for that fiscal year; activity R43 (SBIR); PI COLEMAN, KENNETH; recipient as written: ARIETIS, Boston, MA. Compounds to treat Helicobacter pylori infection source ↗
Jul 8, 2011 NIH award 5R44AI074258-04 FY2011: $999,998 awarded for that fiscal year; activity R44 (SBIR); PI DAHL, THOMAS A; recipient as written: ARIETIS, Boston, MA. Therapy Against Recalcitrant C. albicans Infection source ↗
May 11, 2011 NIH award 5R43DE020880-02 FY2011: $299,157 awarded for that fiscal year; activity R43 (SBIR); PI DAHL, THOMAS A; recipient as written: ARIETIS, Boston, MA. 2-adamantanamine Based Therapeutic for Recurrent Oropharynge source ↗
Jun 25, 2010 NIH award 2R44AI074258-03A2 FY2010: $986,559 awarded for that fiscal year; activity R44 (SBIR); PI DAHL, THOMAS A; recipient as written: ARIETIS, Boston, MA. Therapy Against Recalcitrant C. albicans Infection source ↗
Apr 13, 2010 NIH award 1R43DE020880-01 FY2010: $298,990 awarded for that fiscal year; activity R43 (SBIR); PI DAHL, THOMAS A; recipient as written: ARIETIS, Boston, MA. 2-adamantanamine Based Therapeutic for Recurrent Oropharynge source ↗
Apr 10, 2009 NIH award 5R43AI074258-02 FY2009: $299,600 awarded for that fiscal year; activity R43 (SBIR); PI DAHL, THOMAS A; recipient as written: ARIETIS, Boston, MA. THERAPY AGAINST RECALCITRANT C. albicans INFECTION source ↗